| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Payments of milestone obligations under license agreements | 5,860 | - |
| Purchases of property and equipment | 339 | 142 |
| Net cash and cash equivalents provided by (used in) investing activities | 32,654 | 77,635 |
| Proceeds from term loan, net of issuance costs | 97,750 | - |
| Payment of term loan issuance costs to third parties | 761 | - |
| Proceeds from milestone obligations met under license agreements recognized as an increase to the financing liability | 2,577 | - |
| Proceeds from exercise of common stock options and issuance of common stock under the employee stock purchase plan | 3,901 | 3,422 |
| Net cash and cash equivalents provided by financing activities | 103,467 | 3,422 |
| Net increase (decrease) in cash and cash equivalents | 8,740 | 723 |
| Cash and cash equivalents at beginning of period | 50,817 | - |
| Cash and cash equivalents at end of period | 59,557 | - |
ARS Pharmaceuticals, Inc. (SPRY)
ARS Pharmaceuticals, Inc. (SPRY)